A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study

Figures & data

Table 1 Patient demographic and clinical characteristics (randomized set)

Mean ± standard deviation or n (%)	Vildagliptin (50 mg twice a day)	Gliclazide (80–320 mg/day)
N	279	278
Age, years	54.6±9.3	54.3±9.1
Sex
Men	132 (47.3)	128 (46.0)
Women	147 (52.7)	150 (54.0)
Race
Caucasian	187 (67.0)	173 (62.2)
Asian	68 (24.4)	72 (25.9)
All other	24 (8.6)	33 (11.9)
HbA1c, %	7.0±0.8	6.9±0.8
≤7.5%	205 (73.5)	218 (78.4)
>7.5%	74 (26.5)	60 (21.6)
Fasting plasma glucose, mmol/L	7.9±1.9	7.8±1.9
Body weight, kg	82.5±14.4	83.4±15.4
Body mass index, kg/m^2	30.7±5.0	31.1±5.2
Duration of type 2 diabetes mellitus, years eGFR (MDRD)	4.8±4.1	4.7±3.8
Normal, >80 mL/minute/1.73 m^2	189 (67.7)	180 (64.7)
Mild, ≥50 to ≥80 mL/minute/1.73 m^2	90 (32.3)	97 (34.9)
Cardiovascular history
Hypertension	142 (50.9)	148 (53.2)
Dyslipidemia	115 (41.2)	127 (45.7)

Abbreviations: eGFR, estimated glomerular filtration rate; HbA_1c, glycated hemoglobin; MDRD, Modification of Diet in Renal Disease.